Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00356525 · ClinicalTrials.gov registry record · Phase 2
Chemotherapy Treatment in Re-occurring Non Small Cell Lung Cancer (NSCLC) After Previous Chemotherapy and Surgical Removal of the NSCLC Tumor
A Phase 2 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT00356525 is a Phase 2 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 41 participants.
The verdict
NCT00356525, a Phase 2 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
The purpose of this study is to help answer: * Whether pemetrexed, gemcitabine and/or carboplatin can shrink tumor(s) or make tumor(s) disappear in patients with relapsed lung cancer (lung cancer that has come back after surgical removal and chemotherapy), and to determine how long this will last * Whether pemetrexed, gemcitabine and/or carboplatin can help patients with relapsed lung cancer live longer
Interventions
- DRUG Pemetrexed
- DRUG carboplatin
- DRUG pemetrexed
- DRUG gemcitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2006-09 |
| Est. Completion | 2009-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00356525
The ClinicalTrials.gov registry entry for NCT00356525 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Pemetrexed is the first listed.
NCT00356525 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00356525 about?
NCT00356525 is a clinical study titled "Chemotherapy Treatment in Re-occurring Non Small Cell Lung Cancer (NSCLC) After Previous Chemotherapy and Surgical Removal of the NSCLC Tumor". The purpose of this study is to help answer: * Whether pemetrexed, gemcitabine and/or carboplatin can shrink tumor(s) or make tumor(s) disappear in patients with relapsed lung cancer (lung cancer that has come back after surgical removal and chemotherapy), and to determine how long this will last *...
What is the current status of trial NCT00356525?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2006-09. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00356525?
The interventions under investigation include: Pemetrexed (DRUG), carboplatin (DRUG), pemetrexed (DRUG), gemcitabine (DRUG).
Who is sponsoring clinical trial NCT00356525?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.